Imcyse

Avenue du Pré-Aily 14

4031 Liège Angleur

BE

Imcyse

Foundation date

10/08/2010

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Imcyse develops active targeted immune therapies (ImotopesÔ) that locally inhibit the immune cells involved in the destruction of the diseased organ. The targeted approach and memory effect of the Imcyse technology help to prevent and cure diseases with no current therapeutic alternative, caused by disruptions of the immune system without impairing the patient’s immune defences. 

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    1 day ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022